Anika Therapeutics Downgraded by Thomson Reuters/Verus to Hold (ANIK)
Anika Therapeutics (NASDAQ:ANIK) was downgraded by equities researchers at Thomson Reuters/Verus from a “buy” rating to a “hold” rating in a research report issued on Monday, American Banking and Market News reports.
Anika Therapeutics (NASDAQ:ANIK) traded up 1.36% during mid-day trading on Monday, hitting $30.034. 322,432 shares of the company’s stock traded hands. Anika Therapeutics has a 52 week low of $9.13 and a 52 week high of $31.03. The stock’s 50-day moving average is $25.61 and its 200-day moving average is $20.09. The company has a market cap of $428.5 million and a price-to-earnings ratio of 23.50.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.19. The company had revenue of $17.80 million for the quarter, compared to the consensus estimate of $16.96 million. On average, analysts predict that Anika Therapeutics will post $1.15 earnings per share for the current fiscal year.
Separately, analysts at Summer Street raised their price target on shares of Anika Therapeutics from $28.00 to $35.00 in a research note to investors on Friday. They now have a “buy” rating on the stock.
Anika Therapeutics, Inc (NASDAQ:ANIK) develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.